ATE493978T1 - Behandlung von autoimmunerkrankungen - Google Patents
Behandlung von autoimmunerkrankungenInfo
- Publication number
- ATE493978T1 ATE493978T1 AT99957017T AT99957017T ATE493978T1 AT E493978 T1 ATE493978 T1 AT E493978T1 AT 99957017 T AT99957017 T AT 99957017T AT 99957017 T AT99957017 T AT 99957017T AT E493978 T1 ATE493978 T1 AT E493978T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- autoimmune diseases
- intravenously
- administering
- amino acid
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9000598P | 1998-06-19 | 1998-06-19 | |
| US09/223,069 US6103748A (en) | 1998-06-19 | 1998-12-29 | Method of treating an autoimmune disorder |
| PCT/US1999/012232 WO1999065479A1 (en) | 1998-06-19 | 1999-06-02 | Method of treating an autoimmune disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE493978T1 true ATE493978T1 (de) | 2011-01-15 |
Family
ID=26781225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99957017T ATE493978T1 (de) | 1998-06-19 | 1999-06-02 | Behandlung von autoimmunerkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6103748A (de) |
| EP (1) | EP1085862B1 (de) |
| AT (1) | ATE493978T1 (de) |
| AU (1) | AU760993B2 (de) |
| CA (1) | CA2338533C (de) |
| DE (1) | DE69943107D1 (de) |
| WO (1) | WO1999065479A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6103748A (en) * | 1998-06-19 | 2000-08-15 | Bryan; Thomas B. | Method of treating an autoimmune disorder |
| CA2376029A1 (en) * | 1999-07-13 | 2001-01-18 | Medicure Inc. | Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| CN1489460A (zh) * | 2001-01-30 | 2004-04-14 | 味之素株式会社 | 炎症性疾病治疗预防剂 |
| JP4300753B2 (ja) * | 2001-05-31 | 2009-07-22 | 味の素株式会社 | 貧血抑制剤及び食欲抑制剤 |
| US20060029647A1 (en) * | 2004-02-09 | 2006-02-09 | Friesen Kim G | Composition and method for use in cartilage affecting conditions |
| US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| EP1818053A4 (de) * | 2004-11-02 | 2008-02-27 | Ajinomoto Kk | Mittel zur behandlung/prophylaxe von allergischen erkrankungen |
| US20060148727A1 (en) * | 2004-12-01 | 2006-07-06 | Curt Hendrix | Folate based composition for neurological and cognitive applications |
| EP1716887B1 (de) * | 2005-04-25 | 2008-03-19 | Sahltech I Göteborg AB | Behandlung von Einschlusskörper-Myositis |
| US8148356B2 (en) | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| US7700083B2 (en) * | 2005-10-24 | 2010-04-20 | Kevin Meehan | Skin care composition for accelerated production of collagen proteins and method of fabricating same |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| US8389739B1 (en) | 2006-10-05 | 2013-03-05 | Orphagen Pharmaceuticals | Modulators of retinoid-related orphan receptor gamma |
| CA2764073A1 (en) | 2009-06-30 | 2011-01-20 | E. I. Du Pont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding cytosolic pyrophosphatase |
| AR078829A1 (es) | 2009-10-30 | 2011-12-07 | Du Pont | Plantas y semillas con niveles alterados de compuesto de almacenamiento, construcciones relacionadas y metodos relacionados con genes que codifican proteinas similares a las aldolasas bacterianas de la clase ii del acido 2,4- dihidroxi-hept-2-eno-1,7-dioico |
| BR112012022045A8 (pt) | 2010-03-03 | 2018-06-19 | Du Pont | ''planta transgênica,semente transgênica,método para produzir uma planta transgênica,método para produzir sementes transgênicas,produto e/ou subproduto,polinucleotídeo isolado e planta ou semente''. |
| WO2012003207A2 (en) | 2010-07-01 | 2012-01-05 | E. I. Du Pont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| WO2018226987A1 (en) | 2017-06-07 | 2018-12-13 | The Regents Of The University Of California | Compositions for treating fungal and bacterial biofilms and methods of using the same |
| SG11202001142VA (en) | 2017-08-14 | 2020-03-30 | Axcella Health Inc | Amino acid compositions for the treatment of liver disease |
| MA52971A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
| US11334352B1 (en) | 2020-12-29 | 2022-05-17 | Kpn Innovations, Llc. | Systems and methods for generating an immune protocol for identifying and reversing immune disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB839711A (en) * | 1956-11-19 | 1960-06-29 | Andrew Andor Recsei | Process for the treatment of alcoholic and non-alcoholic beverages |
| JPS5852225A (ja) * | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
| EP0220537B1 (de) * | 1985-10-23 | 1990-07-25 | Dr. Kurt Mulli Nachf. GmbH & Co. KG | Thymusextraktfraktionen enthaltende pharmazeutische Zusammensetzung |
| US5719119A (en) * | 1985-12-18 | 1998-02-17 | British Technology Group, Ltd. | Parenteral nutrition therapy with amino acids |
| DE69331727D1 (de) * | 1992-06-30 | 2002-04-25 | Howard K Shapiro | Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen |
| US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| WO1995031194A1 (en) * | 1994-05-11 | 1995-11-23 | Shapiro Howard K | Compositions for treatment of chronic inflammatory diseases |
| DE4431175A1 (de) * | 1994-09-01 | 1996-04-11 | Medico Pharma Vertriebs Gmbh | Neue, Chelatbildner enthaltende Arzneimittel |
| US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
| US6103748A (en) * | 1998-06-19 | 2000-08-15 | Bryan; Thomas B. | Method of treating an autoimmune disorder |
-
1998
- 1998-12-29 US US09/223,069 patent/US6103748A/en not_active Expired - Lifetime
-
1999
- 1999-06-02 EP EP99957017A patent/EP1085862B1/de not_active Expired - Lifetime
- 1999-06-02 WO PCT/US1999/012232 patent/WO1999065479A1/en active IP Right Grant
- 1999-06-02 DE DE69943107T patent/DE69943107D1/de not_active Expired - Lifetime
- 1999-06-02 CA CA002338533A patent/CA2338533C/en not_active Expired - Fee Related
- 1999-06-02 AU AU43281/99A patent/AU760993B2/en not_active Ceased
- 1999-06-02 AT AT99957017T patent/ATE493978T1/de not_active IP Right Cessation
-
2000
- 2000-05-31 US US09/585,245 patent/US6274612B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2338533A1 (en) | 1999-12-23 |
| CA2338533C (en) | 2009-11-24 |
| US6274612B1 (en) | 2001-08-14 |
| WO1999065479A1 (en) | 1999-12-23 |
| DE69943107D1 (de) | 2011-02-17 |
| EP1085862A4 (de) | 2008-07-23 |
| EP1085862B1 (de) | 2011-01-05 |
| AU760993B2 (en) | 2003-05-29 |
| EP1085862A1 (de) | 2001-03-28 |
| US6103748A (en) | 2000-08-15 |
| AU4328199A (en) | 2000-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69943107D1 (de) | Behandlung von autoimmunerkrankungen | |
| DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| AP1398A (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives. | |
| DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| EA200100721A1 (ru) | Производное габапентина для предупреждения и лечения висцеральной боли | |
| NO20101190L (no) | Anvendelse av buprenorfin i fremstillingen av et medikament | |
| DE60139466D1 (de) | Behandlung von diabetes | |
| PT998287E (pt) | Utilizacao de levobupivacaina | |
| ATE252897T1 (de) | Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen | |
| GEP20053423B (en) | Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| ATE225177T1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria | |
| DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE223721T1 (de) | Edelfosin zur behandlung von hirntumoren | |
| MD970254A (en) | Use of melatonine for treatment of patients having a medicamental dependence | |
| DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
| DE69736180D1 (de) | Behandlung von manischen erkrankungen | |
| ATE302008T1 (de) | Behandlung von entzündlichen erkrankungen | |
| DE69926357D1 (de) | Vorbereitung eines medikaments zur behandlung von refluxösophagitis | |
| DE50003730D1 (de) | Caspase 8-inhibitoren zur immunsuppression | |
| WO2001089500A3 (en) | Agents and methods for increasing brain chaperonin levels | |
| ATE203680T1 (de) | Konjugat zur behandlung von entzündungserkrankungen | |
| DE69813354D1 (de) | Mittel zur Behandlung von Herzkrankheiten | |
| NO961496L (no) | Behandling av allergiske sykdommer med terfenadinkarboksylat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |